In addition, in the combined WES cohort, NRAS mutations were most significantly associated with aggressive disease features, such as leukocytosis (OR = 3.0, CI: 1.7–5.1) and LT risk (OR = 2.7, CI: 1.4–5.3; Fig. 2F), with the number of driver mutations correlating with disease severity in CMML (Fig. 2G). This evidence concerns the gene NRAS and Increased total leukocyte count.